FY2027 Earnings Estimate for ACAD Issued By Leerink Partnrs

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at Leerink Partnrs dropped their FY2027 earnings per share estimates for ACADIA Pharmaceuticals in a research note issued on Sunday, November 17th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of $1.50 for the year, down from their previous forecast of $1.60. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.72 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2028 earnings at $2.15 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.14 by $0.06. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The firm had revenue of $250.40 million during the quarter, compared to analysts’ expectations of $248.83 million. During the same quarter last year, the firm earned ($0.40) earnings per share. The business’s revenue for the quarter was up 18.3% on a year-over-year basis.

Other equities research analysts have also recently issued research reports about the company. Raymond James reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. Cantor Fitzgerald cut their target price on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Citigroup cut their target price on ACADIA Pharmaceuticals from $30.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Finally, StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $25.56.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD opened at $16.27 on Wednesday. The stock has a 50 day moving average price of $15.61 and a 200 day moving average price of $15.99. The stock has a market cap of $2.71 billion, a PE ratio of 20.86 and a beta of 0.38. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $32.59.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Park Place Capital Corp acquired a new position in ACADIA Pharmaceuticals during the 3rd quarter worth approximately $25,000. Values First Advisors Inc. acquired a new position in ACADIA Pharmaceuticals during the 3rd quarter worth approximately $27,000. Covestor Ltd increased its position in ACADIA Pharmaceuticals by 70.5% during the 1st quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 840 shares during the period. Quest Partners LLC increased its position in ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 1,047 shares during the period. Finally, Stonepine Capital Management LLC acquired a new position in ACADIA Pharmaceuticals during the 2nd quarter worth approximately $81,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

Insider Activity

In related news, insider James Kihara sold 4,073 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $68,467.13. Following the transaction, the insider now owns 19,863 shares in the company, valued at $333,897.03. The trade was a 17.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Mark C. Schneyer sold 10,259 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $172,453.79. Following the completion of the transaction, the chief financial officer now owns 53,302 shares in the company, valued at $896,006.62. This trade represents a 16.14 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 24,661 shares of company stock valued at $414,551. Insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.